- Strong FUSILEV® (levoleucovorin) for Injection revenues recorded in Q3. Accounts ordering FUSILEV increased by 13% over last quarter. FUSILEV market penetration at approximately 31% up from 29% in the prior quarter.
- Company expects Pro-Forma Revenue to exceed $300 million in 2012, up from earlier guidance of around $300 million.
- Integration of Allos Therapeutics exceeding expectations. Anticipated synergies are expected to be $50 million or higher, exceeding earlier estimated range of $40 to $50 million.
Insert after Forward-looking statement two financial tables, SPECTRUM PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS and SUMMARY CONSOLIDATED BALANCE SHEETS. The corrected release reads: SPECTRUM PHARMACEUTICALS REPORTS STRONG REVENUES AND PROFITS FOR THIRD QUARTER; REVENUES OF $69 MILLION UP 35% OVER LAST YEAR AND GAAP DILUTED EPS OF $0.33 AND NON-GAAP DILUTED EPS OF $0.42